Offers Claimed: 192
Downloaded Today: 18
Yes91% of Medicare Part D and Medicare Advantage plans cover this drug.
It depends. Which coverage stage are you in? Click on a tab below…
$42 – $464
In the Deductible co-pay stage, you are responsible for the full cost of your prescriptions. Your Medicare deductible cannot exceed $360 in 2016.
Here are some ways that may lower the cost of your anoro ellipta prescription.
If your Medicare co-pay is higher, you can save money by using a USARx coupon instead.
Note: This document contains side effect information about umeclidinium / vilanterol. Some of the dosage forms listed on this page may not apply to the brand name Anoro Ellipta.For the Consumer
Applies to umeclidinium / vilanterol: inhalation powder
Inhalation route (Powder)
Asthma-related death: Long-acting beta(2)-adrenergic agonists (LABA) increase the risk of asthma-related death. Data from a large placebo-controlled US trial that compared the safety of another LABA (salmeterol) with placebo added to the usual asthma therapy showed an increase in asthma-related deaths in subjects receiving salmeterol. This finding with salmeterol is considered a class effect of all LABA, including vilanterol, one of the active ingredients in the umeclidinium/vilanterol combination. The safety and efficacy of umeclidinium / vilanterol in patients with asthma have not been established. Umeclidinium / vilanterol is not indicated for the treatment of asthma.
Along with its needed effects, umeclidinium / vilanterol may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking umeclidinium / vilanterol:
Some side effects of umeclidinium / vilanterol may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
For Healthcare Professionals
Applies to umeclidinium / vilanterol: inhalation powderGeneral
The most common adverse reaction was nasopharyngitis (9%).Endocrine
Common (1% to 10%): Diabetes MellitusGastrointestinal
Common (1% to 10%): Constipation, dry mouth, diarrhea, nausea, abdominal pain, toothache
Uncommon (0.1% to 1%): Dyspepsia, gastroesophageal reflux disease, vomitingGenitourinary
Common (1% to 10%): Urinary tract infection
Frequency not reported: Signs and symptoms of urinary retention (e.g., difficulty passing urine, painful urination)Musculoskeletal
Common (1% to 10%): Pain in extremity, muscle spasms, neck pain, back pain, arthralgia
Uncommon (0.1% to 1%): Musculoskeletal chest painNervous system
Common (1% to 10%): Headache
Postmarketing reports: Dysgeusia, tremorOther
Common (1% to 10%): Vertigo
Uncommon (0.1% to 1%): AstheniaRespiratory
Common (1% to 10%): Pharyngitis, sinusitis, nasopharyngitis, lower respiratory tract infection, upper respiratory tract infections, cough, chest pain, pleuritic pain, viral respiratory tract infection, oropharyngeal pain
Uncommon (0.1% to 1%): Productive cough, chest discomfort
Frequency not reported: Paradoxical bronchospasmCardiovascular
Uncommon (0.1% to 1%): Atrial fibrillation, ventricular extrasystoles, supraventricular extrasystoles, myocardial infarction, rhythm idioventricular, tachycardia, supraventricular tachycardia
Frequency not reported: Symptoms of increases in pulse rate, systolic or diastolic blood pressure
Postmarketing reports: PalpitationsDermatologic
Uncommon (0.1% to 1%): Pruritus, rashOcular
Uncommon (0.1% to 1%): Conjunctivitis
Frequency not reported: Worsening of narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema)Hypersensitivity
Postmarketing reports: Hypersensitivity reactions, including anaphylaxis, angioedema, and urticariaPsychiatric
Postmarketing reports: Anxiety
August 4, 2022
August 4, 2022
August 4, 2022
July 26, 2022
July 26, 2022
July 22, 2022